KR900005009B1 - 지속성 서방출형 약제학적 조성물 - Google Patents

지속성 서방출형 약제학적 조성물 Download PDF

Info

Publication number
KR900005009B1
KR900005009B1 KR1019870000682A KR870000682A KR900005009B1 KR 900005009 B1 KR900005009 B1 KR 900005009B1 KR 1019870000682 A KR1019870000682 A KR 1019870000682A KR 870000682 A KR870000682 A KR 870000682A KR 900005009 B1 KR900005009 B1 KR 900005009B1
Authority
KR
South Korea
Prior art keywords
alkyl
pharmaceutical composition
sustained
calcium pathway
binder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
KR1019870000682A
Other languages
English (en)
Korean (ko)
Other versions
KR870007121A (ko
Inventor
비.마크 파리안 캘럼
비.셀키르크 아리스테어
제이.데이 미첼
Original Assignee
신텍스(유.에스.에이.)인코포레이티드
알란 엠.크루바이너
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 신텍스(유.에스.에이.)인코포레이티드, 알란 엠.크루바이너 filed Critical 신텍스(유.에스.에이.)인코포레이티드
Publication of KR870007121A publication Critical patent/KR870007121A/ko
Application granted granted Critical
Publication of KR900005009B1 publication Critical patent/KR900005009B1/ko
Expired legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/82Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1019870000682A 1986-01-30 1987-01-28 지속성 서방출형 약제학적 조성물 Expired KR900005009B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82389686A 1986-01-30 1986-01-30
US94087886A 1986-12-10 1986-12-10
US940,878 1986-12-10
US823,896 1992-01-22

Publications (2)

Publication Number Publication Date
KR870007121A KR870007121A (ko) 1987-08-17
KR900005009B1 true KR900005009B1 (ko) 1990-07-16

Family

ID=27124769

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870000682A Expired KR900005009B1 (ko) 1986-01-30 1987-01-28 지속성 서방출형 약제학적 조성물

Country Status (18)

Country Link
EP (1) EP0231026B1 (enExample)
JP (1) JP2524990B2 (enExample)
KR (1) KR900005009B1 (enExample)
AU (1) AU604672B2 (enExample)
CA (1) CA1285227C (enExample)
DE (1) DE3782439T2 (enExample)
DK (1) DK175216B1 (enExample)
ES (1) ES2052500T3 (enExample)
FI (1) FI88872C (enExample)
GR (1) GR3006148T3 (enExample)
HU (1) HU196709B (enExample)
IE (1) IE61879B1 (enExample)
IL (2) IL81419A0 (enExample)
IT (1) IT1206876B (enExample)
NO (1) NO174325C (enExample)
NZ (1) NZ219090A (enExample)
PH (1) PH26366A (enExample)
PT (1) PT84213B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940556A (en) * 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
JP2804048B2 (ja) * 1987-09-11 1998-09-24 イー・アール・スクイブ・アンド・サンズ・インコーポレイテッド 高薬物含量医薬組成物およびその製造法
JP2528706B2 (ja) * 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
US4925676A (en) * 1989-02-02 1990-05-15 Warner-Lambert Company Extended release gemfibrozil composition
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
JPH0729926B2 (ja) * 1989-07-25 1995-04-05 大塚製薬株式会社 易吸収性製剤用組成物
FI943121L (fi) * 1991-12-30 1994-06-29 Fmc Corp Mikrokiteinen selluloosa -sferonisointikoostumus
JP3623805B2 (ja) * 1992-02-20 2005-02-23 ユーロセルテイツク・エス・アー ヒドロモルホンスフェロイド調整放出製剤
GB9203689D0 (en) * 1992-02-20 1992-04-08 Euro Celtique Sa Pharmaceutical composition
TW474824B (en) * 1996-09-13 2002-02-01 Basf Ag The production of solid pharmaceutical forms
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
ATE400251T1 (de) 1999-02-09 2008-07-15 Pfizer Prod Inc Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit
EP1830886B1 (en) 2004-12-27 2016-04-13 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795766A (fr) * 1972-02-22 1973-08-22 Lilly Co Eli Particules de napsylate de propoxyphene retard et procede de fabrication de ces particules
JPS5846019A (ja) * 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
FR2581541B1 (fr) * 1985-05-09 1988-05-20 Rhone Poulenc Sante Nouvelles compositions pharmaceutiques permettant la liberation prolongee d'un principe actif et leur procede de preparation

Also Published As

Publication number Publication date
PT84213A (en) 1987-02-01
FI870380A0 (fi) 1987-01-29
GR3006148T3 (enExample) 1993-06-21
PT84213B (pt) 1989-03-30
IE61879B1 (en) 1994-11-30
NO174325C (no) 1994-04-20
FI88872C (fi) 1993-07-26
HU196709B (en) 1989-01-30
FI870380L (fi) 1987-07-31
DE3782439T2 (de) 1993-05-19
EP0231026A1 (en) 1987-08-05
HUT42950A (en) 1987-09-28
ES2052500T3 (es) 1994-07-16
NO870368D0 (no) 1987-01-29
IT8767057A0 (it) 1987-01-29
JP2524990B2 (ja) 1996-08-14
JPS62252732A (ja) 1987-11-04
AU604672B2 (en) 1991-01-03
IL81419A (en) 1991-07-18
CA1285227C (en) 1991-06-25
IL81419A0 (en) 1987-08-31
AU6810287A (en) 1987-08-06
NO870368L (no) 1987-07-31
DE3782439D1 (de) 1992-12-10
KR870007121A (ko) 1987-08-17
EP0231026B1 (en) 1992-11-04
DK47787D0 (da) 1987-01-29
NO174325B (no) 1994-01-10
IT1206876B (it) 1989-05-11
NZ219090A (en) 1990-04-26
DK175216B1 (da) 2004-07-12
PH26366A (en) 1992-06-01
IE870229L (en) 1987-07-30
DK47787A (da) 1987-07-31
FI88872B (fi) 1993-04-15

Similar Documents

Publication Publication Date Title
US4940556A (en) Method of preparing long acting formulation
US5198226A (en) Long acting nicardipine hydrochloride formulation
KR900005009B1 (ko) 지속성 서방출형 약제학적 조성물
US5209933A (en) Long acting calcium channel blocker composition
JP2637981B2 (ja) 吸収制御薬剤組成物
JP4852423B2 (ja) 固体の経口投与可能な医薬組成物の製造方法
CA1312286C (en) Pharmaceutical preparation containing metoprolol
RU2235540C2 (ru) Способ получения пероральной препаративной формы пролонгированного действия с регулируемым высвобождением активного вещества в зависимости от вида и количества наполнения желудка и пищеварительного тракта
DK167649B1 (da) Fast laegemiddeldispersion med forlaenget afgivelse, sekundaer struktur af laegemidlet samt farmaceutisk praeparat indeholdende dispersionen eller strukturen
JPH0521886B2 (enExample)
US6048547A (en) Process for manufacturing solid compositions containing polyethylene oxide and an active ingredient
JPH0122245B2 (enExample)
CA2011919A1 (en) A drug-release controlling coating material for long acting formulations
JP2003519681A (ja) グルブリド組成物
KR970001656B1 (ko) 조절흡수 딜티아젬 제제
JP2009532462A (ja) 調節放出クロピドグレル製剤
JP3110794B2 (ja) 1,4−ジヒドロピリジン誘導体を含有する製剤
WO1989002738A1 (en) Sustained-release nifedipine formulation
WO2001076557A1 (en) Sustained release preparations
PT1178780E (pt) Formulações de inibidores selectivos da reassimilação de serotonina, de libertação controlada e multiparticularidades
BR112014020184B1 (pt) Preparação farmacêutica que contém anlodipina e ra-mipril
WO2005053659A1 (en) An improved pharmaceutical formulation containing tamsulosin salt and a process for its preparation
WO2006085208A2 (en) Stable solid dosage forms of amlodipine and benazepril
JPH10120571A (ja) 塩酸ジルチアゼム徐放性製剤
JPWO2002060448A1 (ja) 医薬組成物

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19870128

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19870917

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19870128

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19900129

Patent event code: PE09021S01D

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19900613

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19901005

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19901101

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19901101

End annual number: 3

Start annual number: 1

PR1001 Payment of annual fee

Payment date: 19930323

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 19940629

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 19950630

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 19960628

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 19970630

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 19980629

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 19990630

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20000629

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20010707

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20020708

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20030701

Start annual number: 14

End annual number: 14

PR1001 Payment of annual fee

Payment date: 20040701

Start annual number: 15

End annual number: 15

PR1001 Payment of annual fee

Payment date: 20050630

Start annual number: 16

End annual number: 16

FPAY Annual fee payment

Payment date: 20060630

Year of fee payment: 17

PR1001 Payment of annual fee

Payment date: 20060630

Start annual number: 17

End annual number: 17

EXPY Expiration of term
PC1801 Expiration of term